We are interested in multiple alliance structures that can build upon and expand on the Alluminox™ platform to advance treatment options for patients with cancer.
Therapies or devices that can be incorporated into our Alluminox™ platform and tumor microenvironment.
Therapies that can be developed in combination with our lead drug, ASP-1929.
Companies that can assist in the clinical development and commercialization of our lead product, ASP-1929, in specific geographic territories.
Centers of excellence that can participate in the clinical development and enrollment of our clinical trials for investigational products developed on the Alluminox™ platform.
Links to past events and presentations hosted by Rakuten Medical.
10JAN23 – 41st Annual J.P. Morgan Healthcare Conference ( Presentation / Audio Recording)
10JAN22 - 40th Annual J.P. Morgan Healthcare Conference ( Webcast /Presentation )
11JAN21 - 39th Annual J.P. Morgan Healthcare Conference
19JAN21 - VP Global Corporate and Business Development (Abhijit Bhatia) - Price of Business Interview
DISCLAIMER: Outside of Japan, ASP-1929 photoimmunotherapy is investigational